Treatment of Herpes Simplex Virus Infections in Pediatric Patients: Current Status and Future Needs

Herpes simplex virus type 1 (HSV‐1) and type 2 (HSV‐2) are members of the Herpesviridae family and are characterized by their ability to establish latency after primary infection and subsequently reactivate. HSV infections in the neonatal and pediatric populations range from uncomplicated mucocutane...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2010-11, Vol.88 (5), p.720-724
Hauptverfasser:	James, S H, Whitley, R J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Age Factors Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Biological and medical sciences Child Child, Preschool Drug Administration Schedule Herpes Simplex - drug therapy Herpes Simplex - mortality Herpes Simplex - virology Herpesvirus 1, Human - drug effects Herpesvirus 1, Human - pathogenicity Herpesvirus 2, Human - drug effects Herpesvirus 2, Human - pathogenicity Human viral diseases Humans Infant Infant, Newborn Infectious diseases Medical sciences Pharmacology. Drug treatments Recurrence Severity of Illness Index Time Factors Treatment Outcome Viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye Virus Activation Virus Latency
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Herpes simplex virus type 1 (HSV‐1) and type 2 (HSV‐2) are members of the Herpesviridae family and are characterized by their ability to establish latency after primary infection and subsequently reactivate. HSV infections in the neonatal and pediatric populations range from uncomplicated mucocutaneous diseases to severe, life‐threatening infections involving the central nervous system (CNS). The antiviral agent acyclovir has significantly improved treatment outcomes of HSV infections, including the frequency of mucocutaneous recurrences and mortality associated with CNS and disseminated infections. Clinical Pharmacology & Therapeutics (2010) 88 5, 720–724. doi: 10.1038/clpt.2010.192
ISSN:	0009-9236 1532-6535
DOI:	10.1038/clpt.2010.192